ANA. Y. Nirupama

A. Y. Nirupama

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


A. Y. Nirupama has a total of 20 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    From Polycystic Ovary Syndrome to Polyendocrine Metabolic Ovarian Syndrome: A Change with Healthcare Implications

    by A. Y. Nirupama, Vinoth Gnana Chellaiyan Devanbu, Jennifer Britto John

    Was not provided for this article.

  • Open Access

    Health-related quality of life (HRQoL) of women with breast cancer undergoing treatment in a tertiary care centre in India

    by Abhilash Patra, Shona Nag, Shriniwas Subhash Kulkarni, Rebecca DeSouza, Hira B. Pant, Varun Agiwal, A. Y. Nirupama, G. V. S. Murthy

    Introduction: Breast cancer in India accounts for 178361 of all cancers (Globocan 2020 report). Treatment causes financial, social, and psychological stress, impacting patients’ quality of life (QoL). Multiple studies have reported QoL among survivors, however few studies focused on patients undergoing treatment in India. Hence, the present study aimed to measure the QoL and its influencing factors associated with breast cancer undergoing various treatments in the oncology department of a tertiary care hospital in India. Methods: A hospital-based cross-sectional study (Nov 2022 - Jan 2023) used a semi-structured questionnaire on participants’ sociodemographic and clinical characteristics. The validated Marathi and English EORTC QLQ-C30 and BR23 assessed QoL. Participants were selected using convenience sampling. Results: A total of 285 patients agreed to participate with a mean age of 54.2 ± 12.2 years and the mean score of Global Health Status (GHS)/QoL was 54.4 ± 19.6. Patients who received radiation had more pain ( p < 0.001), insomnia ( p < 0.001), and diarrhoea ( p = 0.005), whereas, those who received chemotherapy had higher scores in constipation ( p < 0.001) and loss of appetite ( p = 0.001). Co-morbidities were significantly associated with breast cancer-specific symptoms scales – upset by hair loss ( p = 0.025), arm symptoms ( p = 0.026), and breast symptoms ( p = 0.013). Conclusion: Education, occupation, hours of sleep, financial issues, and type of surgery were linked to the patient’s QoL. Therefore, these patients require additional attention and support services, including effective pain management and interventions to enhance sleep quality, to further enhance their QoL. Longitudinal studies incorporating detailed clinical and psychosocial variables are needed to understand the determinants of QoL.

  • Open Access

    Continued Efficacy Of Nitrofurantoin And Co-Trimoxazole For Community-Acquired Urinary Tract Infections Amid Rising Antimicrobial Resistance In Southern India

    by Sambit Sahu, Pratik Patil, Sumit Ray, Aditi, Seema M Gafurjiwala, Nirupama A Y, Rajan Shukla, Raghavendra Rao M V

    Background: Urinary tract infections (UTIs) impose a substantial global burden, contributing to significant morbidity and accelerating antimicrobial resistance (AMR), particularly in regions like Southern India where resistance patterns are evolving rapidly. Objectives: This study aimed to elucidate long-term trends in the microbiological etiology and antimicrobial susceptibility of community-acquired UTIs (CA-UTIs) among outpatients in Southern India from 2014 to 2022, thereby informing evidence-based empirical treatment guidelines and enhancing antibiotic stewardship efforts. Methods: A retrospective observational analysis was conducted on 5,550 unique outpatient urine cultures positive for CA-UTI at a tertiary care hospital in Secunderabad, Southern India. Pathogens were identified and susceptibility tested using the Vitek 2 Compact system, interpreted per CLSI guidelines. Results: Escherichia coli dominated (64.2%), followed by Klebsiella pneumoniae (19.5%). E. coli susceptibility to nitrofurantoin remained consistently high at ~80%, and to co-trimoxazole increased to 52% by 2022. In contrast, third-generation cephalosporin susceptibility (e.g., cefotaxime, ceftriaxone) declined from 44% (2014) to 30% (2022), and ciprofloxacin susceptibility fell from 33% to 18%. K. pneumoniae showed low nitrofurantoin susceptibility (~30%) but improved co-trimoxazole susceptibility to 56% by 2022. Extended-spectrum beta-lactamase (ESBL) rates were 30% in E. coli and 40% in K. pneumoniae, with carbapenem and amikacin susceptibility >85% for E. coli. Conclusion: Nitrofurantoin and co-trimoxazole retain efficacy as first-line empirical therapies for uncomplicated CA-UTIs in this region. Ongoing local surveillance is imperative to combat escalating AMR.


  • Development of a Study Tool to Measure Awareness of Human Papillomavirus Vaccine Among Cancer Patients and Their Intention to Recommend the Vaccine

    by Syeda S. Ali, Krishna Mohan Mallavarapu, A. Y. Nirupama

    Background Literature suggests that there is poor awareness and uptake of the Human Papillomavirus (HPV) vaccine in India. The role of cancer patients as potent advocates for HPV vaccine in their community is vital due to their first-hand experience with the turmoil that accompanies cancer. Hence, we have developed a study tool to measure the psychometric constructs “Awareness” of HPV vaccine among cancer patients and “Intention” to recommend the vaccine. Methods The theoretical concepts of the Health Belief Model were applied, feedback from oncologists at Basavatarakam Indo-American Cancer Hospital and Research Institute and public health experts at Indian Institute of Public Health to develop the study tool. A 24 items study tool was finalized following pre-testing and content validation. A sample size of 5:1 (participant:item) was considered adequate to conduct exploratory factor analysis (EFA). The pilot study tool was administered for validation to 150 cancer patients visiting the hospital during June–July 2023. The data were analysed using Jamovi (Version2.3). Results The McDonald’s omega was 0.8, which indicates good internal consistency of the data. EFA using parallel analysis with maximum likelihood extraction method and Promax oblique rotation with factor loadings above 0.4 revealed a 3-factor solution with 21 items. Factors were named “Capability”, “Awareness” and “Risk perception” respectively. The correlation between “Awareness” and “Risk Perception” was 0.28; between “Capability” and “Risk perception” 0.47. “Awareness” and “Capability” had a weak negative correlation(-0.02). Conclusions The study tool could effectively measure individual constructs of awareness and intention. Notably, our findings indicate a weak correlation between awareness and one component of intention (capability), within this population. This aspect, rigorously measured and validated by our study tool, holds significance as it implies that despite a low level of awareness in this population, they may still be considered as potentially influential advocates for the HPV vaccine.